|
Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Oncosil (I) |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca (Inst) |
Patents, Royalties, Other Intellectual Property - Hold a patent related to a novel treatment target in ovarian cancer |
| |
|
Consulting or Advisory Role - MSD |
| |
Christos Stelios Karapetis |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Roche |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - AstraZeneca; Janssen; Merck |
| |
|
Honoraria - Boehringer Ingelheim |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Exo Therapeutics |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Roche (Inst) |
| |
|
No Relationships to Disclose |
| |
|
|
Travel, Accommodations, Expenses - Merck Serono |